Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028 Report Highlights:
- Global CD276 Antibody Market Opportunity Assessment: > US$ 1 Billion
- Global CD276 Antibody Expected Drug Approvals
- Global CD276 Antibody Clinical Trials: > 30 Drugs In Trials
- Targeting CD276 Through Monotherapy, Combination & Targeted Therapy
- CD276 Antibodies Orphan & Priority Status Review
- Global CD276 Antibody Clinical Trials By Company, Indication & Phase
- Insight On 25 Companies Involved in Development of CD276 Antibodies
With the rapidly evolving landscape of cancer treatment, the introduction of immunotherapy in field has advanced the treatment options, expanding the number of opportunities as well as redefining the cancer treatment regimen. Immunotherapy has resulted in remarkable durable responses across different cancer indications, revolutionizing the treatment over the decade. Immune checkpoint approach has seen the major success ratio in comparison to others and has since then become a constant area of research.
Pursuit for novel immune checkpoint targets that can possibly have a therapeutic effect on cancer are never stopping, which has led to the discovery of CD276 also known as B7-H3 (B7 Homolog 3 protein) immune checkpoint. Belonging to the family of B7 immune checkpoints, its inhibition has shown to have anti-tumorigenic effect. Even though there has been no FDA approved checkpoint inhibitor for CD276, the presence of robust clinical pipeline suggests that the availability of first ever CD276 checkpoint inhibitor is not too far.
Even with limited knowledge about the structure of CD276, there are approximately 30 drug candidates currently undergoing clinical trials for respective cancer indications where each of them is being evaluated in terms of safety, efficacy and improvement in overall survival rates. Furthermore, the studies are not limited to its clinical efficacy but they are also investigating the prognostic value of its expression on tumor cells. Multiple studies have suggested a possible correlation between poor clinical prognosis and CD276 and for now, the expression of Cd276/B7-H3 has been widely studies in case of non-small cell lung cancer.
The therapeutic potential of Cd276 immune checkpoint has caught the eye of the pharmaceutical industry and companied have progressed their research for their particular drug candidates. For instance, Bio-Thera Solutions has announced that it has started first patient dose for its drug BAT8009, an antibody drug conjugate that targets CD276 (B7-H3) in phase I study for the treatment of patients with advanced solid tumors.
Difference in the expression level of CD276 on tumor cells and healthy cells has made it a potential target for antibody drug conjugate drug development. BAT8009 was developed using Bio-Thera’s proprietary technology and the phase I multicenter, open label, dose escalation clinical trial is designed to assess the safety and tolerability of the drug. Furthermore, this clinical trial will also determine the dose for recommended and expected phase II.
The discovery of CD276 immune checkpoint has released the arrival of several preclinical studies just waiting to be cleared and move forward to in-human clinical trials. The extensive study on the therapeutic possibility of CD276 has been done on for several cancers but not just limited to lung cancer, breast cancer, ovarian cancer, kidney cancer, brain tumor, gastric tumor and squamous cell carcinoma. With advancements in molecular biology and innovation in antibody engineering have facilitated the targeting of CD276 immune checkpoint by several mechanisms.
Moreover, the clinical trials are not limited to determing the monotherapeutic potential of CD276 targeting immune checkpoint inhibitors but combinational approaches are also being tested and favoured for several cancer indications. For instance, MGA271, a CD276/B7-H3 directed immune checkpoint inhibitor drug is being tested in combination with Yervoy (Ipilumumab) in several indications including non-small cell lung cancer to evaluate the safety and efficacy of this combinational use.
The robust clinical pipeline promises that soon there will be an immune checkpoint inhibitor drug that will be targeting CD276. Furthermore, the growing research and development activities and increasing adoption towards the development of novel therapeutic strategies have anticipated the arrival of CD276 immune checkpoint inhibitor in the market. This report provides an in0depth analysis about the current ongoing clinical trials being conducted in the area and also providing future insights about the most expected CD276 targeted therapy and what will be the future market potential of this drug.